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Purpose: Apoptosis has been implicated as the mechanism for retinal ganglion cell death in primary open-angle glaucoma
(POAG), a complex neurodegenerative disease. There have been inconsistent reports regarding increased risk of POAG
and a polymorphism (Arg72Pro) within the tumor suppressor gene, p53. The goal of this study was to examine the role
of this polymorphism in susceptibility to POAG in a Caucasian population from the United States.
Methods: We generated genotypes in 191 unrelated Caucasian POAG patients and 167 unrelated Caucasian controls for
the following polymorphisms within p53: rs1042522 (Arg72Pro), rs17878362 (16 bp Ins/Del), and rs1800371 (Pro47Ser)
by PCR amplification followed by restriction digestion and sequence analysis.
Results: There was a significant difference in genotypic frequencies for rs1042522 (Arg72Pro) between POAG patients
and controls (χ2= 9.56, p=0.008). Individuals who were homozygous for the arginine allele have a 1.9 fold significantly
increased risk of developing glaucoma (95%CI: 1.16-2.82, p=0.01). Interestingly, we found that the frequency of the
arginine allele was even higher in the normal-tension glaucoma (NTG) subtype compared to high-tension POAG (0.81
versus 0.76).
Conclusions: Our preliminary results indicate that the arginine variant of rs1042522 within p53 is associated with
increased risk of POAG. This variant has increased apoptotic potential, thus the retinal ganglion cells in carriers of the
arginine allele may have greater susceptibility to apoptosis.
Glaucoma, the second leading cause of blindness in the
world, includes a group of eye disorders characterized by
visual  field  defects,  retinal  ganglion  cell  death,  and
progressive  degeneration  of  the  optic  nerve.  Adult-onset
primary open-angle glaucoma (POAG) represents the most
prevalent form of glaucoma, and affects 33 million individuals
worldwide [1]. It is recognized that POAG is a multi-factorial
disorder  involving  the  role  of  multiple  genes  as  well  as
environmental  factors.  The  major  risk  factors  for  the
development of POAG include advanced age, race, elevated
intraocular pressure (IOP), and family history. Genome-wide
linkage analysis in families with an autosomal dominant form
of POAG have resulted in identification of eight chromosomal
regions that harbor genes involved in POAG [2-9]. To date,
mutations  in  three  genes  (myocilin  [MYOC],  optineurin
[OPTN], and WD repeat domain 36 [WDR36]) have been
found to be associated with POAG [8,10,11]. However, these
mutations only account for 3-5% of all POAG cases [12].
Thus, the genetic basis of the majority of POAG cases remains
unknown.
The death of retinal ganglion cells in glaucoma has been
the  subject  of  extensive  research,  which  has  implicated
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apoptosis  as  the  pathway  for  programmed  cell  death
(reviewed in [13]). One of the important regulatory proteins
in apoptosis is the tumor suppressor protein p53, known as the
“guardian of the genome”. p53 can promote apoptosis through
a  transcription-dependent  mechanism  or  independent  of
transcriptional  regulation.  Under  normal  conditions,  p53
levels and activity are tightly regulated. Upon diverse forms
of cellular stress the steady state levels and transcriptional
activity of p53 are considerably increased. Moreover, it has
been  shown  that  p53  is  active  in  retinal  ganglion  cells.
Specifically, elevated levels of p53 have been detected within
the  inner  retina  after  transient  retinal  ischemia  [14].  In
heterozygote  mice  with  a  p53  null  mutation,  there  was
significant resistance to ischemia and preservation of the inner
retinal layer [14].
Interestingly, p53 has been implicated in development of
POAG.  There  have  been  inconsistent  reports  regarding
increased  risk  of  glaucoma  and  genetic  variations  within
p53. An association was originally detected between POAG
and a SNP in exon 4 of p53 at codon 72 (rs1042522-Arg72Pro)
in a Chinese population [15]. However, two additional groups
did not observe this association in a group of Indian and
Tasmanian POAG patients [16,17]. Examination of a 16 base
pair (bp) insertion/deletion polymorphism located within p53
intron 3 (rs17878362) has provided suggestive evidence that
a specific haplotype based on this variation and the p53 exon
4 SNP is associated with POAG [16,18]. However, it should
be  noted  that  each  of  these  studies  examined  different
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1939ethnicities  from  outside  of  United  States.  Data  from  the
Hapmap  project  for  this  SNP  confirms  differences  in
genotypic and allelic frequencies between different ethnic
groups.
The goal of this study was to examine the association
between  POAG  and  several  SNPs  within  p53  in  a  large
Caucasian  population  recruited  at  the  West  Virginia
University  Eye  Institute  that  have  the  unique  feature  of
representing the Appalachian population. In our cohort, there
is evidence for an association between POAG risk and the p53
Arg72Pro polymorphism based on the results provided below.
METHODS
This study was reviewed and approved by the West Virginia
University Institutional Review Board. All subjects provided
written informed consent and authorization to use protected
health  information.  For  this  retrospective  case-control
association study, subjects with primary open-angle glaucoma
and  subjects  without  glaucoma  were  recruited  from  the
glaucoma and the comprehensive clinics of the WVU Eye
Institute.  All  subjects  underwent  ophthalmic  examination
including assessment of visual acuity and intraocular pressure
(IOP) by Goldmann tonometry, slit-lamp inspection of the
anterior chamber, and dilated fundoscopic evaluation of the
optic nerve and retina. The medical records of all subjects
were  carefully  reviewed  to  determine  historical  IOP
measurements and any historical diagnosis of glaucoma or
suspicion  of  glaucoma.  All  subjects  also  completed  a
questionnaire detailing their ophthalmic and medical history
as well as the ophthalmic history of their family including the
presence  of  glaucoma  in  their  siblings,  parents,  children,
grandparents, aunts, and uncles. Subjects with glaucoma or
suspected  glaucoma  underwent  additional  evaluation
including  assessment  of  central  corneal  thickness,
gonioscopy,  and  standard  automated  perimetry  using  the
SITA-Standard  24-2  or  30-2  testing  algorithm  on  the
Humphrey  Field  Analyzer  II.  To  minimize  perimetry
learning-effect artifacts, all subjects were experienced with
automated perimetry, and only reliable visual fields (defined
as fewer than 20% fixation losses, false-positives, and false-
negatives with no obvious artifacts such as those attributable
to trial lens rim or lid droop) were included for analysis.
Subjects were classified as having primary open-angle
glaucoma  based  on  the  presence  of  all  of  the  following:
anterior chamber angles open by gonioscopy, reproducible
visual field defects (arcuate, nasal step, or temporal wedge
defects or generalized constriction) on standard perimetry,
and  glaucomatous  optic  neuropathy  (focal  thinning  or
notching of the Neuroretinal rim, generalized enlargement of
the optic cup, presence of a disc hemorrhage, focal nerve fiber
layer bundle defects, or inter-eye asymmetry of the cup-disc
ratio exceeding 0.2). Glaucoma subjects with IOP never being
recorded  over  21  mmHg  were  considered  normal  tension
glaucoma subjects as a subgroup of the open angle glaucoma
patients. Subjects were classified as non-glaucomatous if all
of the following criteria were met: no history of IOP above 21
mmHg, no findings consistent with conditions associated with
secondary glaucoma (such as pigment dispersion syndrome,
pseudoexfoliation  syndrome,  uveitis,  or  anterior  segment
neovascularization); and no evidence of glaucomatous optic
neuropathy as described above. Subjects with some but not all
of the primary open-angle glaucoma criteria were classified
as glaucoma suspects, as were subjects with IOP above 21
mmHg  in  the  absence  of  either  visual  field  defects  or
glaucomatous  optic  neuropathy;  these  glaucoma  suspects
were excluded from analysis.
All subjects underwent venipuncture to obtain a blood
sample for genetic analysis. Genomic DNA was extracted
from peripheral blood leukocytes by the Gentra Puregene
Blood  kit  (Qiagen,  Valencia,  CA)  according  to  the
manufacturer’s  protocol.  We  obtained  genotypes  for  the
following  polymorphisms  within  p53:  1)  rs1042522
(Arg72Pro, G→C, exon 4); 2) rs17878362 (16 bp Ins/Del,
intron 3); and 3) rs1800371 (Pro47Ser, C→T, exon 4). In each
case, the polymorphism was detected by PCR followed by
restriction  digestion  analysis  (Table  1).  In  some  samples,
genotypes were confirmed by direct sequencing.
For  each  polymorphism,  genotypic  distributions  were
examined for significant departure from the Hardy-Weinberg
equilibrium by χ2 analysis for patients and controls. Genotypic
and allelic frequencies were compared between POAG cases
and controls by χ2 analysis. Odds ratios were calculated using
a conditional logistic model, adjusting for age and sex. All
analyses were conducted using SPSS software (Release 15.0;
SPSS Inc., Chicago, IL).
RESULTS
Our cohort consisted of 167 unrelated Caucasian controls and
191 unrelated Caucasian POAG patients, of whom 52 had
NTG. Subject characteristics are summarized in Table 2. The
majority of subjects were of European descent and had the
unique feature of representing the Appalachian population.
TABLE 1. PRIMER SEQUENCE AND RESTRICTION ENZYMES USED FOR GENOTYPING THE POLYMORPHISMS WITHIN P53.
SNP Distance Enzyme F-primer R-primer
rs1042522 0 BstUI GTGGGAAGCGAAAATTCCAT GCCAGGCATTGAAGTCTCAT
rs1800371 -76 MspI GACCTGTGGGAAGCGAAAAT GAGCAGCCTCTGGCATTCT
rs17878362 -172 BstUI GTGGGAAGCGAAAATTCCAT GCCAGGCATTGAAGTCTCAT
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1940Although patients were older than controls in our study, the
controls were older than the average age of diagnosis and were
still free of any signs of POAG. Cases were screened for the
presence  of  the  3  most  frequent  mutations  in  MYOC:
Gly364Val, Gln368Stop, and Tyr437His and no carriers were
detected for these mutations.
We examined genotypic and allelic frequencies for the
Arg72Pro SNP (rs1042522) within p53 in our cohort, which
were in Hardy-Weinberg equilibrium in both POAG patients
and controls. There is a significant difference in genotypic
frequencies  for  rs1042522  between  POAG  patients  and
controls  (χ2=  9.56,  p=0.008;  Table  3).  There  were  49%
homozygotes  for  arginine,  43%  hetreozygotes  and  8%
homozygotes for proline among controls as compared to 65%
homozygotes  for  arginine,  29%  hetreozygotes  and  6%
homozygotes for proline among POAG patients. The allelic
frequencies were 71% for arginine and 29% for proline in the
controls compared to 80% for arginine and 20% for proline in
POAG.  The  frequency  of  the  arginine  allele  (G)  is
significantly  increased  in  POAG  patients  compared  to
controls (p≤0.01). Interestingly, the frequency of the arginine
allele is even higher in the NTG subtype compared to the high-
tension POAG (0.84 versus 0.78).
Individuals who were homozygous for the arginine allele
had a significant 1.95 fold increased risk of developing POAG
than those who are heterozygous or lack the arginine allele
(95%CI: 1.27 – 2.98, p=0.002). Since there are differences in
age and proportion of females between patients and controls,
we examined allele frequencies by sex and by age groups. The
frequency of the arginine allele (G) was increased in POAG
patients compared to controls in both men and women (Figure
1A). For age comparisons, we grouped the subjects into 2 age
groups: group 1 from 50-64 years old and group 2 from 65-99
years old. In both age groups, the frequency of the arginine
allele  (G)  was  increased  in  POAG  patients  compared  to
controls (Figure 1B). The age- and sex-adjusted odds ratio
indicate that homozygotes for the arginine allele still had a
significant  1.92  fold  increased  risk  of  developing  POAG
(95%CI: 1.22–3.0, p=0.005). We wondered if the association
would be stronger in POAG patients with a positive family
history  of  POAG.  The  allelic  frequencies  were  85%  for
arginine and 15% for proline in those with a positive family
history compared to 77% for arginine and 23% for proline in
those without a family history. Although the frequency of the
arginine allele was slightly elevated, it was not significant.
Next, we examined rs17878362 which is a 16 bp Ins/del
that is 172 bp away from rs1042522. There were no significant
differences in genotypic or allelic frequencies for this SNP
(Table  4).  However,  there  was  a  specific  haplotype
(rs1042522:  arginine  and  rs17878362:  Del)  that  was
significantly more frequent among POAG cases than controls
(0.78 versus 0.69, p=0.01). The presence of the risk haplotype
(arginine/Del)  was  associated  with  a  1.6  fold  significant
increased risk of developing glaucoma (95%CI: 1.14-2.23,
p=0.01). We also examined rs1800371 (exon 4: Ser47Pro) as
it is a non-synonymous SNP in the same exon as rs1042522,
but did not detect a carrier for the rare proline allele in our
cohort.
DISCUSSION
It is well recognized that POAG is a multi-factorial disease
and it is expected that multiple genes will contribute to its
susceptibility. The goal of this study was to examine the role
of the p53 Arg72Pro SNP (rs1042522) in susceptibility to
POAG.  In  our  cohort,  we  have  detected  evidence  for  an
association between the arginine variant and increased risk of
POAG. This association was not affected by differences in
gender or age between cases and controls in our sample. The
inclusion of rs17878362 (an Ins/del polymorphism located in
intron 3) did not result in a haplotype that had a stronger effect
on POAG risk than the Arg72Pro coding SNP located in exon
TABLE 2. SUBJECT CHARACTERISTICS.
Demographic features Controls All POAG POAG-HTG POAG-NTG
N 167 191 139 52
Females 63% 48% 42% 65%
Age at Inclusion 60.3±12.0 67.5±12.5 66.6±12.6 69.8±12.0
Age at Diagnosis 58.8±18.9 58.1±20.7 60.9±12.5
Family history of POAG 18% 35% 36% 31%
TABLE 3. GENOTYPIC AND ALLELE FREQUENCIES IN POAG PATIENTS AND CONTROLS FOR RS1042522.
Genotype/Allele Controls All POAG POAG-HTG POAG-NTG
G/G 0.49 0.65 0.64 0.69
G/C 0.43 0.29 0.29 0.29
C/C 0.08 0.06 0.07 0.02
G (Arg) 0.71 0.80 0.78 0.84
C (Pro) 0.29 0.20 0.22 0.16
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19414.  In  this  study,  patients  and  controls  were  matched  for
ethnicity  to  avoid  confounding  due  to  population
stratification.  All  subjects  were  Caucasian  and  a  majority
resided in the same geographical location and represent the
Appalachian population. Moreover, the allele frequencies for
the Arginine and Proline variants in our controls were similar
to  the  allele  frequencies  in  Caucasian  samples  from  the
Hapmap data.
Our results are in contrast to the initial study by Lin et al.
[15]  where  increased  frequency  of  the  proline  allele
(rs1042522)  was  detected  in  POAG  cases  compared  to
controls. One of the reasons for the discrepancy may be the
difference in ethnic populations in each study. According to
the Hapmap data, the frequency of the arginine and proline
allele  are  0.51  and  0.49,  respectively,  in  the  Chinese
population, and 0.77 and 0.23 in the Caucasian population of
European origin. The allele frequencies among controls in our
cohort are similar to those from the Hapmap data. Although
Acharya et al. [16] did not detect a significant difference in an
Indian  population;  they  observed  a  trend  for  increased
frequency of the arginine allele (rs1042522) and the Del allele
(rs17878362). Interestingly, in a Caucasian population from
England, Ressiniotis et al. [18] observed increased frequency
of the arginine allele in POAG cases compared to controls in
subjects  with  the  16  bp  insertion  allele  (rs17878362).
However, the finding of the lack of an association between
this SNP (rs1042522) and POAG in the sample by Dimasi et
Figure  1.  Allele  Frequencies  for
rs1042522  in  POAG  patients  and
controls  by  sex  and  age.  A:  The
frequency of the arginine allele (G) and
proline allele (C) in men and women. In
both men and women, the frequency of
the  arginine  allele  (G)  is  higher  in
POAG  patients  than  controls.  B:
Subjects  were  divided  into  two  age
groups: group 1 from 50-64 years old
and group 2 from 65-99 years old. In
both age groups, the frequency of the
arginine allele (G) is higher in POAG
patients than controls.
Molecular Vision 2009; 15:1939-1944 <http://www.molvis.org/molvis/v15/a206> © 2009 Molecular Vision
1942al. [17], which is contrary to our results can not be easily
explained.
p53 is one of the key regulators of apoptosis. It can either
arrest cell cycle progression in the late G1 phase, thus allowing
the  DNA  to  be  repaired  before  replication,  or  induce
apoptosis, leading to cell death. This polymorphism occurs in
the proline-rich domain of p53, which is necessary for the
protein to fully induce apoptosis. Dumont et al. [19] found that
the Arg72 variant had up to 15 fold increased apoptotic ability
compared with the Pro72 variant in both inducible cell lines
and cells with endogenous p53 homozygous for each variant.
They  suggested  that  at  least  one  source  of  this  enhanced
apoptotic potential is the greater ability of the Arg72 variant
to localize to mitochondria; this localization was accompanied
by release of cytochrome c into the cytosol. Another study had
noted  that  Pro72  variant  was  a  stronger  inducer  of
transcription  than  the  Arg72  variant,  whereas  the  Arg72
variant  induced  apoptosis  faster  and  was  a  more  potent
suppressor  of  transformation  than  the  Pro72  variant  [20].
Thus, it is possible that the finding of an association between
increased risk of POAG in those homozygous for the Arg72
variant  may  be  due  to  increased  susceptibility  of  retinal
ganglion cells to apoptosis. Interestingly, Dimasi et al. [17]
had suggested that a genetic mechanism favoring apoptosis
would have a greater role in NTG in which raised IOP is not
present. In our cohort, we observed even higher frequencies
of the Arginine allele in POAG cases with NTG compared to
HTG although this must be interpreted with caution as the
number of NTG cases is relatively small.
An additional independent evidence for involvement of
p53 in development of POAG comes from studies of zebrafish
mutants lacking functional alleles of WDR36, a gene in which
mutations are associated with small number of POAG cases.
In these mutants, increase expression of a specific p53 isoform
was detected along with the observation that loss of WDR36
function lead to activation of the p53 stress–response pathway
[21].
Further studies consisting of large independent samples
with sufficient statistical power for detection of an association
and a more detailed analysis of genetic variations within p53
are warranted in order to determine if the association is with
Arg72Pro or other alleles in linkage disequilibrium and to
determine its role in the pathogenesis of POAG.
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